Potential role of Fbxo22 in resistance to endocrine therapy in breast cancer with invasive lobular carcinoma.
Nakagawa S, Miyashita M, Maeda I, Goda A, Tada H, Amari M, Kojima Y, Tsugawa K, Ohi Y, Sagara Y, Sato M, Ebata A, Harada-Shoji N, Suzuki T, Nakanishi M, Ohta T, Ishida T.
Nakagawa S, et al. Among authors: harada shoji n.
Breast Cancer Res Treat. 2024 Apr;204(3):453-463. doi: 10.1007/s10549-023-07209-2. Epub 2024 Jan 5.
Breast Cancer Res Treat. 2024.
PMID: 38180699
Free PMC article.